Use of dihydro-isobenzofuran in combination with serotonin reuptake inhibitors for CNS disease e.g. depression, anxiety, bipolar disorder, obsessive compulsory disorder

Klaus P Bøgesø; K Juhl; H Zhong; Claus Juul Løland

Use of dihydro-isobenzofuran in combination with serotonin reuptake inhibitors for CNS disease e.g. depression, anxiety, bipolar disorder, obsessive compulsory disorder

Klaus P Bøgesø (Inventor), K Juhl (Inventor), H Zhong (Inventor), Claus Juul Løland (Inventor)

Neuropharm and Genetics

Abstract

NOVELTY - For treatment of a CNS disease in a patient, dihydro-isobenzofuran compound (I) in combination with serotonin reuptake inhibitor, is used.

USE - For treatment of CNS disease (claimed) including depression, anxiety, bipolar disorder, obsessive compulsory disorder, post traumatic stress disorder and social anxiety disorder.

ADVANTAGE - The compound (I) potentiates the effect of compound that inhibits serotonin reuptake; and selectively modulates the allosteric site at the serotonin transporter.

DETAILED DESCRIPTION - For treatment of a CNS disease in a patient, dihydro-isobenzofuran compound of formula (I) in combination with serotonin reuptake inhibitor, is used.

Original language	English
IPC	C07D-307/79
Patent number	WO2013110313-A1
Country/Territory	Denmark
Priority date	21/08/2013
Priority number	WOEP050952
Publication status	Published - 2013

Cite this

@misc{5ff565e95380463184f5e2cd50ccf4b8,

title = "Use of dihydro-isobenzofuran in combination with serotonin reuptake inhibitors for CNS disease e.g. depression, anxiety, bipolar disorder, obsessive compulsory disorder",

abstract = "NOVELTY - For treatment of a CNS disease in a patient, dihydro-isobenzofuran compound (I) in combination with serotonin reuptake inhibitor, is used.USE - For treatment of CNS disease (claimed) including depression, anxiety, bipolar disorder, obsessive compulsory disorder, post traumatic stress disorder and social anxiety disorder.ADVANTAGE - The compound (I) potentiates the effect of compound that inhibits serotonin reuptake; and selectively modulates the allosteric site at the serotonin transporter.DETAILED DESCRIPTION - For treatment of a CNS disease in a patient, dihydro-isobenzofuran compound of formula (I) in combination with serotonin reuptake inhibitor, is used.",

author = "B{\o}ges{\o}, {Klaus P} and K Juhl and H Zhong and L{\o}land, {Claus Juul}",

year = "2013",

language = "English",

type = "Patent",

note = "WO2013110313-A1; C07D-307/79",

}

TY - PAT

T1 - Use of dihydro-isobenzofuran in combination with serotonin reuptake inhibitors for CNS disease e.g. depression, anxiety, bipolar disorder, obsessive compulsory disorder

AU - Bøgesø, Klaus P

AU - Juhl, K

AU - Zhong, H

AU - Løland, Claus Juul

PY - 2013

Y1 - 2013

N2 - NOVELTY - For treatment of a CNS disease in a patient, dihydro-isobenzofuran compound (I) in combination with serotonin reuptake inhibitor, is used.USE - For treatment of CNS disease (claimed) including depression, anxiety, bipolar disorder, obsessive compulsory disorder, post traumatic stress disorder and social anxiety disorder.ADVANTAGE - The compound (I) potentiates the effect of compound that inhibits serotonin reuptake; and selectively modulates the allosteric site at the serotonin transporter.DETAILED DESCRIPTION - For treatment of a CNS disease in a patient, dihydro-isobenzofuran compound of formula (I) in combination with serotonin reuptake inhibitor, is used.

AB - NOVELTY - For treatment of a CNS disease in a patient, dihydro-isobenzofuran compound (I) in combination with serotonin reuptake inhibitor, is used.USE - For treatment of CNS disease (claimed) including depression, anxiety, bipolar disorder, obsessive compulsory disorder, post traumatic stress disorder and social anxiety disorder.ADVANTAGE - The compound (I) potentiates the effect of compound that inhibits serotonin reuptake; and selectively modulates the allosteric site at the serotonin transporter.DETAILED DESCRIPTION - For treatment of a CNS disease in a patient, dihydro-isobenzofuran compound of formula (I) in combination with serotonin reuptake inhibitor, is used.

M3 - Patent

M1 - WO2013110313-A1

ER -